Organogenesis

ORGO Healthcare Drug Manufacturers Specialty & Generic

Organogenesis' revenue for fiscal 2025 (year ended December 2025) was $564.2 million, up 17.0% from fiscal 2024. In the quarter to June 2026, revenue fell 56.7%, EPS fell 670.0%, free cash flow grew 10.3% and total debt rose 10,940.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.00 0.11 −9.91%
Market cap
$142.8M
P/E
0.0×
Fwd P/E
−2.6×
Dividend yield
—
F-score
4/9
Altman Z
3.03
Beneish M
−1.41
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Total current assets
362.19 285.94 225.04 222.61 226.98 174.34 125.60 71.13 49.74 1.44
Total non-current assets
236.54 211.95 234.98 226.75 216.28 115.87 95.09 92.55 98.98 —
Total Assets
598.73 497.89 460.03 449.36 443.26 290.22 220.69 163.68 148.72 —
Total current liabilities
100.12 77.48 80.51 75.02 82.71 68.22 59.89 56.10 51.97 0.48
Total non-current liabilities
198.48 157.51 100.85 108.67 119.22 80.19 105.21 60.54 112.07 —
Total liabilities
298.60 234.99 181.36 183.69 201.92 148.41 165.10 116.64 157.28 —
Common Equity (Total)
300.13 262.90 278.66 265.67 241.34 141.81 55.58 47.04 (15.32) 5.00
Shareholders Equity (Total)
300.13 262.90 278.66 265.67 241.34 141.81 55.58 47.04 (8.55) —
Total Debt
12.79 0.72 68.12 70.77 73.43 84.77 100.61 71.29 101.47 —

Show all line items

In millions of $ except per-share values · columns are period end dates